Honigman Advises Decoy Therapeutics on up to $21 Million PIPE Financing

Honigman represented Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D‑MAVs™), in connection with a private investment in public equity (PIPE) financing pursuant to a securities purchase agreement with a health care focused institutional investor.

The transaction closed on June 29, 2026 and provided approximately $3.5 million in gross proceeds at closing, with the potential to yield up to an additional approximately $17.5 million upon the exercise of certain milestone-based warrants, for total potential proceeds of up to approximately $21 million.

Curvature Securities LLC acted as the sole placement agent in connection with the transaction. The Honigman team was led by Corporate Partners Jeffrey Kuras and Michael J. Rosenberg, with support from Associates Isaac (Yitzhak) Pasha and Shane Werner.